Stocktoria
Pasithea Therapeutics Corp. KTTA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-08-13
Pasithea Therapeutics Corp. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $486,559 | $15,062 |
| Gross profit | — | — | — | — | -$2,213 |
| R&D expense | $8.0M | $7.2M | $8.1M | $2.7M | — |
| SG&A expense | — | $7.1M | $7.9M | $9.9M | $4.5M |
| Operating income | -$20.9M | -$14.2M | -$16.0M | -$12.6M | -$4.5M |
| Interest expense | — | — | — | $102 | $508 |
| Net income | -$20.4M | -$13.9M | -$16.0M | -$13.9M | -$2.2M |
| EPS (diluted) | $-2.91 | $-12.69 | $-0.42 | $-1.76 | $-0.21 |
| Operating cash flow | -$15.2M | -$13.9M | -$12.8M | -$14.6M | -$3.2M |
| Free cash flow | — | — | -$12.8M | -$14.7M | -$3.2M |
| Cash & equivalents | $55.2M | $6.9M | $16.3M | $33.1M | $53.0M |
| Total assets | $60.2M | $16.1M | $26.1M | $45.2M | $53.3M |
| Total liabilities | $5.0M | $1.3M | $2.7M | $2.7M | $1.9M |
| Shareholders' equity | $55.2M | $14.8M | $23.4M | $42.5M | $51.4M |
Source: SEC EDGAR filings · CIK 0001841330 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.